











## **Prior Authorization Request Administrative Information**

Member Information					
Last name	First name		МІ		
Member ID	Date of birth				
Sex assigned at birth Female Male "X" or Intersex					
Current gender  Female  Male  Transgender male  Transgender female  Other					
Place of residence					
Race/ethnicity Preferred spoken language Preferred written language					
MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).					
Plan Contact Information					
Please indicate the member's MassHealth Plan according to the Plan's contact information belo		his completed and signed	form		
MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan					
☐ MassHealth Drug Utilization Review Prog	gram				
Pharmacy: Fax: (877) 208-7428 - Tel: (800	Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318				
MassHealth Managed Care Organization	n (MCO) and Acco	untable Care Partnershi	p Plans (ACPP)		
☐ Fallon Health					
Online Prior Authorization: go.covermymeds.com/OptumRx					
Online Prior Authorization: providerportal.surescripts.net/ProviderPortal/optum					
Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033					
☐ Health New England					
Online Prior Authorization: go.covermymed	Online Prior Authorization: go.covermymeds.com/OptumRx				
Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545					
Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx					
Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org					
Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555					
☐ Tufts Health Plan					
Online Prior Authorization: point32health.promptpa.com					
Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985					
☐ WellSense Health Plan					
Online Prior Authorization: wellsense.org/p	roviders/ma/pharma	acy/prior-authorizations			
Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822					

## **Dermatological Agents (Topical Chemotherapy and Genital Wart** Therapy)

## **Prior Authorization Request**

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be

found within the MassHealth Drug List at www.	.mass.gov/druglist.
Medication requested ☐ imiquimod 3.75% cream ☐ Veregen (sinecatechins)	<ul><li>☐ Ycanth (cantharidin) MB</li><li>☐ Zyclara (imiquimod 2.5% cream)</li></ul>
inpatient hospital setting. MassHealth does not p listed, prior authorization does not apply through 130 CMR 433.408 for prior authorization require above, this drug may be an exception to the unif	professional who administers the drug or in an outpatient or pay for this drug to be dispensed through the retail pharmacy. If the hospital outpatient and inpatient settings. Please refer to ments for other health care professionals. Notwithstanding the field pharmacy policy; please refer to respective MassHealth and Managed Care Organizations (MCOs) for prior authorization
Dose, frequency, and duration of medication	requested
Indication (Check all that apply) or ICD-10 cod	•
☐ Actinic keratosis	☐ Molluscum contagiosum
External genital warts	Other
☐ Perianal warts	(Attach a letter regarding medical necessity.)
	(/ illaem a feller regarding medical medecity.)
Section I. Please complete for treatment	of actinic keratosis with imiquimod 3.75% cream, or
Zyclara.	
1. Has the member had a trial with topical fluoro	
Yes. Please list the dates/duration of use	and outcomes below.
Dates/duration	Adverse reaction Inadequate response Other
Briefly describe details of adverse reaction, in	nadequate response, or other.
☐ No. Please document if there is a contrain	ndication to topical fluorouracil therapy.
2. If the request is for imiquimod 3.75% cream of	or Zyclara, has the member tried imiquimod 5% cream?
Yes. Please list the dates/duration of use	and outcomes below.
Dates/duration	☐ Adverse reaction ☐ Inadequate response ☐ Other
Briefly describe details of adverse reaction, in	·
No. Please document if there is a contrain	ndication to imiquimod 5% cream.
_	·
J.	

PA-59 (Rev. 04/24) over

Sec	tion II. Please complete for Ycanth requests.				
1.	Has the member had a trial with topical podofilox?				
	Yes. Please list the dates/duration of use and outcomes below.				
	Dates/duration Adverse reaction Inadequate response Other				
	Briefly describe details of adverse reaction, inadequate response, or other.				
	No. Please document if there is a contraindication to topical podofilox.				
2.	Has the member tried and failed cryotherapy? ☐ Yes ☐ No				
3.	Has the member tried and failed curettage? ☐ Yes ☐ No				
Sec	tion III. Please complete for treatment of external genital warts or perianal warts with				
	imiquimod 3.75% cream or Veregen.				
1.	Has the member had a trial with topical podofilox, or podophyllum resin applied by a provider?				
	Yes. Please list the dates/duration of use and outcomes below.				
	Drug name				
	Dates/duration Adverse reaction Inadequate response Other				
	Briefly describe details of adverse reaction, inadequate response, or other.				
	☐ No. Please document if there is a contraindication to topical podofilox and podophyllum resin.				
2.	If the request is for imiquimod 3.75% cream, has the member had a trial with imiquimod 5% cream?				
	Dates/duration Adverse reaction Inadequate response Other				
	Briefly describe details of adverse reaction, inadequate response, or other.				
	Zinony docume di darana i adrana i adrana i adaptina i adaptina i adrana i adaptina i adrana				
	No. Places decument if there is a contraindication to imiguimed 50/ groom				
	No. Please document if there is a contraindication to imiquimod 5% cream.				
<u> </u>	tion IV. Disease complete and provide decomposition for expositions to Ctan Thomass.				
<b>Sec</b>	tion IV. Please complete and provide documentation for exceptions to Step Therapy.  Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an				
١.	adverse reaction in, or physical or mental harm to the member?   Yes No				
	If yes, briefly describe details of contraindication, adverse reaction, or harm.				
	if yes, briefly describe details of contrallidication, adverse reaction, of flatfit.				
2.	Is the alternative drug required under the step therapy protocol expected to be ineffective based on the				
۷.	known clinical characteristics of the member and the known characteristics of the alternative drug regimen?				
	Yes No				
	☐ res ☐ NO  If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.				
	ii yes, briefiy describe details of known climical characteristics of member and alternative drug regimen.				

3.	Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such					
	alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse					
	event?					
	☐ Yes ☐ No					
	If yes, please provide details for the previous trial.					
	Drug name Dates/duration of use					
Did the member experience any of the following?   Adverse reaction   Inadequate response						
	Briefly describe details of adverse reaction or inadequate response.					
4. Is the member stable on the requested prescription drug prescribed by the health care provider, and						
switching drugs will likely cause an adverse reaction in or physical or mental harm to the member?						
	Yes. Please provide details.					
	No					

Please continue to next page and complete Prescriber and Provider Information section.

## **Prior Authorization Request Prescriber and Provider Information**

Prescriber Information				
Last name*	First name* MI			
NPI*	Individual MH Provider ID			
DEA No.	Office Contact Name			
Address	City State Zip			
Email address				
Telephone No.* * Required	Fax No.*			
Please also complete for professionally adm	inistered medications, if applicable.			
Start date	End date			
Servicing prescriber/facility name	☐ Same as prescribing provider			
Servicing provider/facility address				
Servicing provider NPI/tax ID No.				
Name of billing provider				
Billing provider NPI No.				
Is this a request for recertification? ☐ Yes ☐ No				
CPT code No. of visits	J code No. of units			
Prescribing provider's attestation, signature, and date				
I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.				
Prescribing provider's signature				
Printed name of prescribing provider	Date			

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)